Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience
- PMID: 31553772
- PMCID: PMC6760782
- DOI: 10.1371/journal.pone.0223287
Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0215783.].
Erratum for
-
SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.PLoS One. 2019 May 15;14(5):e0215783. doi: 10.1371/journal.pone.0215783. eCollection 2019. PLoS One. 2019. PMID: 31091254 Free PMC article.
References
-
- Mangia A, Piazzolla V, Giannelli A, Visaggi E, Minerva N, Palmieri V, et al. (2019) SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience. PLoS ONE 14(5): e0215783 10.1371/journal.pone.0215783 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
